Natrunix + Placebo
Phase 2Recruiting 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Axial Spondyloarthritis
Conditions
Axial Spondyloarthritis
Trial Timeline
Aug 15, 2026 → Apr 30, 2027
NCT ID
NCT06526377About Natrunix + Placebo
Natrunix + Placebo is a phase 2 stage product being developed by XBiotech for Axial Spondyloarthritis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06526377. Target conditions include Axial Spondyloarthritis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06526377 | Phase 2 | Recruiting |
| NCT05363891 | Phase 2 | Completed |
Competing Products
20 competing products in Axial Spondyloarthritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SUNPG1622 I dose + Placebo dose | Sun Pharmaceutical | Phase 2 | 52 |
| Brodalumab + Placebo | Kyowa Kirin | Phase 3 | 77 |
| Ixekizumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Ixekizumab + Placebo | Eli Lilly | Phase 3 | 77 |
| SHR0302 + SHR0302 placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| SHR-1314 | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| Upadacitinib | AbbVie | Pre-clinical | 23 |
| Adalimumab | AbbVie | Approved | 85 |
| Adalimumab + Placebo + Open-label Adalimumab | AbbVie | Phase 3 | 77 |
| adalimumab + Placebo | AbbVie | Phase 3 | 77 |
| Treatment | Merck | Pre-clinical | 23 |
| Golimumab | Merck | Phase 3 | 77 |
| Tulisokibart + Placebo | Merck | Phase 2 | 52 |
| Secukinumab 150 milligram [Cosentyx] | Novartis | Approved | 85 |
| secukinumab | Novartis | Pre-clinical | 23 |
| Secukinumab + Placebo | Novartis | Phase 3 | 77 |
| Secukinumab + Placebo + Secukinumab | Novartis | Approved | 85 |
| Secukinumab + Secukinumab and Placebo | Novartis | Phase 3 | 77 |
| Secukinumab/Adalimumab-Biosimilar | Novartis | Phase 3 | 77 |
| Brodalumab 210 mg + Placebo | Amgen | Phase 2 | 51 |
Other Products from XBiotech
Natrunix with MTX placebo (+folate) + Natrunix placebo with MTX (+folate)Phase 2
44
Natrunix 400 mg + Placebo + Methotrexate (MTX)Phase 2
44
Natrunix + PlaceboPhase 2
44
XB2001 or PlaceboPhase 1/2
33
514G3 (2 mg/kg) plus standard IV antibiotic treatment + 514G3 (10 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase IIPhase 1/2
33